Want to see TSE:JNH full AI Analyst Report?
Top Page
Jack Nathan Medical
(JNH)
Select Model
Select Model
Rating:40Underperform
Price Target:
C$0.01
▲(0.00% Upside)
Action:N/A
Date:12/11/25
Jack Nathan Medical's overall stock score of 40 reflects significant challenges, primarily driven by poor financial performance with a steep revenue decline, negative cash flows, and weak profitability. Technical analysis indicates limited momentum and high volatility, while valuation metrics highlight unprofitability with a negative P/E ratio. Investors should approach with caution due to these substantial risks.
Positive Factors
Strategic Partnership
The strategic partnership with Walmart provides a competitive advantage by reducing overhead costs and increasing patient foot traffic, which can enhance long-term revenue potential and market reach.
Negative Factors
Revenue Decline
Declining revenues indicate a contraction in business operations, which could impact long-term growth and market position if not addressed.
Read all positive and negative factors
Positive Factors
Negative Factors
Strategic Partnership
The strategic partnership with Walmart provides a competitive advantage by reducing overhead costs and increasing patient foot traffic, which can enhance long-term revenue potential and market reach.
Read all positive factors
Jack Nathan Medical (JNH) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$413.49K
Dividend YieldN/A
Average Volume (3M)0.00
Price to Earnings (P/E)―
Beta (1Y)0.44
Revenue GrowthN/A
EPS GrowthN/A
CountryCA
Employees24
SectorHealthcare
Sector Strength45
IndustryMedical - Care Facilities
Share Statistics
EPS (TTM)-0.01
Shares Outstanding87,099,160
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)5.64
Price to Sales (P/S)0.86
P/FCF Ratio-0.99
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Jack Nathan Medical Business Overview & Revenue Model
Company Description
Jack Nathan Medical Corp. (JNH.V), along with its affiliated entities, primarily delivers primary healthcare services under the Jack Nathan Health brand. These medical clinics are predominantly located within Walmart Supercentres. As of June 30, 2...
How the Company Makes Money
Jack Nathan Medical generates revenue primarily through the provision of healthcare services to patients who visit its clinics. The company bills provincial health insurance plans for covered services, which constitutes a significant portion of it...
Jack Nathan Medical Financial Statement Overview
Summary
Income Statement
35
Negative
Balance Sheet
40
Negative
Cash Flow
30
Negative
| Breakdown | TTM | Apr 2025 | Jan 2024 | Apr 2023 | Apr 2022 | Apr 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 3.45M | 8.71M | 19.14M | 15.49M | 9.64M | 3.85M |
| Gross Profit | 3.02M | 7.37M | 14.48M | 11.82M | 6.92M | 3.74M |
| EBITDA | -985.39K | -1.54M | -4.96M | -5.51M | -7.54M | -10.11M |
| Net Income | 9.37M | 7.46M | -6.64M | -7.08M | -7.81M | -9.90M |
Balance Sheet | ||||||
| Total Assets | 1.56M | 3.54M | 11.19M | 6.45M | 10.65M | 406.78K |
| Cash, Cash Equivalents and Short-Term Investments | 802.39K | 2.20M | 3.07M | 1.46M | 7.69M | 406.78K |
| Total Debt | 206.06K | 243.31K | 12.39M | 4.55M | 713.02K | 713.02K |
| Total Liabilities | 1.47M | 2.22M | 17.13M | 8.32M | 2.13M | 17.18K |
| Stockholders Equity | 89.66K | 1.32M | -5.95M | -1.87M | 8.53M | 389.59K |
Cash Flow | ||||||
| Free Cash Flow | -5.34M | -7.54M | -10.20M | -4.59M | -1.31M | -566.27K |
| Operating Cash Flow | -4.73M | -6.36M | -6.11M | -2.00M | -809.16K | -66.53K |
| Investing Cash Flow | 5.01M | 4.45M | -4.09M | -2.69M | -252.89K | -252.89K |
| Financing Cash Flow | -52.07K | 1.04M | 11.91M | 5.28M | 8.68M | 389.11K |
Jack Nathan Medical Technical Analysis
Negative
0.01
Price Trends
0.01
Negative
0.01
Negative
0.01
Negative
Market Momentum
>-0.01
Neutral
100.00
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:JNH, the sentiment is Negative. The current price of 0.01 is below the 20-day moving average (MA) of 0.01, below the 50-day MA of 0.01, and below the 200-day MA of 0.01, indicating a bearish trend. The MACD of >-0.01 indicates Neutral momentum. The RSI at ― is undefined, neither overbought nor oversold. The STOCH value of 100.00 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:JNH.
Jack Nathan Medical Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
74 Outperform | C$206.88M | 7.62 | 25.79% | 2.51% | 2.96% | ― | |
71 Outperform | C$46.28M | 26.34 | 6.95% | ― | 18.35% | 1021.05% | |
62 Neutral | C$1.07B | 164.03 | 0.44% | ― | 38.54% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
40 Underperform | C$413.49K | -0.70 | -699.38% | ― | ― | ― |
* Healthcare Sector Average
TSE:JNH
Jack Nathan Medical
0.01
0.00
0.00%
TSE:CRRX
CareRx
3.27
-0.11
-3.25%
TSE:NLH
Nova Leap Health
0.56
0.22
64.71%
TSE:WELL
WELL Health Technologies Corp
4.15
-0.55
-11.70%
TSE:CALM
Revitalist Lifestyle & Wellness Ltd
0.02
0.00
0.00%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.